Drugs from the deep: marine natural products as drug candidates

Mayer, 2000, Marine pharmacology, The Pharmacologist, 42, 62

Proksch, 2002, Drugs from the sea – current status and microbiological implications, Appl. Microbiol. Biotechnol., 59, 125, 10.1007/s00253-002-1006-8

Jones, 2000, Conotoxins – new vistas for peptide therapeutics, Curr. Pharm. Des., 6, 1249, 10.2174/1381612003399653

McIntosh, 2001, Cone venom – from accidental stings to deliberate injection, Toxicon, 39, 1447, 10.1016/S0041-0101(01)00145-3

Jain, 2000, An evaluation of intrathecal Ziconotide for the treatment of chronic pain, Expert Opin. Investig. Drugs, 9, 2403, 10.1517/13543784.9.10.2403

Hale, 2002, The chemistry and biology of the bryostatin antitumour macrolides, Nat. Prod. Rep., 19, 413, 10.1039/b009211h

Clamp, 2002, The clinical development of the bryostatins, Anticancer Drugs, 13, 673, 10.1097/00001813-200208000-00001

Davidson, 2001, Evidence for the biosynthesis of bryostatins by the bacterial symbiont ‘Candidatus Endobugula sertula’ of the bryozoan Bugula neritina, Appl. Environ. Microbiol., 67, 4531, 10.1128/AEM.67.10.4531-4537.2001

Evans, 1999, Synthesis of bryostatin-2, J. Am. Chem. Soc., 121, 7540, 10.1021/ja990860j

Ohmori, 2000, Total synthesis of bryostatin-3, Angew. Chem. Int. Ed. Engl., 39, 2290, 10.1002/1521-3773(20000703)39:13<2290::AID-ANIE2290>3.0.CO;2-6

Kageyama, 1990, Synthesis of bryostatin-7, J. Am. Chem. Soc., 112, 7407, 10.1021/ja00176a058

Meijer, 2000, Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constitutent, Chem. Biol., 7, 51, 10.1016/S1074-5521(00)00063-6

Tasdemir, 2002, Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1), J. Med. Chem., 45, 529, 10.1021/jm0102856

Breton, 1997, The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-κB, J. Pharmacol. Exp. Ther., 282, 459

Roshak, 1997, Inhibition of NF-κB-mediated interleukin-1β-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine, J. Pharmacol. Exp. Ther., 283, 955

Stevenson, 2002, Scytonemin – a marine natural product inhibitor of kinases key in hyperproliferative inflammatory disease, Inflamm. Res., 51, 112, 10.1007/BF02684014

Stevenson, 2002, The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore, J. Pharmacol. Exp. Ther., 303, 858, 10.1124/jpet.102.036350

Kreuter, 1990, Inhibition of intrinsic protein tyrosine kinase activity of EGF-receptor kinase complex from human breast cancer cells by the marine sponge metabolite (+)-aeroplysinin-1, Comp. Biochem. Physiol. B, 97, 151, 10.1016/0305-0491(90)90194-X

Hinterding, 1998, Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors, Bioorg. Med. Chem., 6, 1153, 10.1016/S0968-0896(98)00070-4

Rodriguez-Nieto, 2002, Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge, FASEB J., 16, 261, 10.1096/fj.01-0427fje

Lee, 1992, Marine sponge polyketide inhibitors of protein tyrosine kinase, Biochem. Biophys. Res. Commun., 184, 765, 10.1016/0006-291X(92)90656-6

Slate, 1994, The marine natural product halistanol trisulfate inhibits pp60v-src protein tyrosine kinase activity, Biochem. Biophys. Res. Commun., 184, 260, 10.1006/bbrc.1994.2176

Wessels, 1999, A new tyrosine kinase inhibitor from the marine brown alga Stypopodium zonale, J. Nat. Prod., 62, 927, 10.1021/np990010h

Osterhage, 2000, Ascosalipyrrolidinone A, an antimicrobial alkaloid, from the obligate marine fungus Ascochyta salicorniae, J. Org. Chem., 65, 6412, 10.1021/jo000307g

Balsinde, 1999, Regulation and inhibition of phospholipase A2, Annu. Rev. Pharmacol. Toxicol., 39, 175, 10.1146/annurev.pharmtox.39.1.175

Toqui, 2001, Mammalian secreted phospholipase A2 and their pathophysiological significance in inflammatory diseases, Curr. Mol. Med., 1, 739, 10.2174/1566524013363258

Soriente, 1999, Manoalide, Curr. Med. Chem., 6, 415, 10.2174/0929867306666220320223452

Escrig, 1997, Variabilin: a dual inhibitor of human secretory and cytosolic phospholipase A2 with antiinflammatroy activity, J. Pharmacol. Exp. Ther., 282, 123

Garcia-Pastor, 1999, Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2, Br. J. Pharmacol., 126, 301, 10.1038/sj.bjp.0702302

Randazzo, 1998, Petrosaspongiolides M-R: new potent and selective phospholipase A2 inhibitors from the New Caledonian marine sponge Petrosaspongia nigra, J. Nat. Prod., 61, 571, 10.1021/np9704922

Garcia-Pastor, 1999, Effects of Petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation, J. Pharmacol. Exp. Ther., 289, 166

Giannini, 2001, New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte functions, J. Nat. Prod., 64, 612, 10.1021/np000637w

Potts, 1992, Phospholipase A2 inhibitors from marine organisms, J. Nat. Prod., 55, 1701, 10.1021/np50090a001

Lifeng, 2001, Novel molecules that interact with microtubules and have functional activity similar to Taxol™, Drug Discov. Today, 6, 1153, 10.1016/S1359-6446(01)02038-4

Poncet, 1999, The dolastatins, a family of promising antineoplastic agents, Curr. Pharm. Des., 5, 139, 10.2174/1381612805666230109214008

Luesch, 2002, The cyanobacterial origin of potent anticancer agents originally isolated from sea hares, Curr. Med. Chem., 9, 1791, 10.2174/0929867023369051

Bai, 1991, Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data, J. Biol. Chem., 266, 15882, 10.1016/S0021-9258(18)98491-7

Mooberry, 1999, Laulimalide and isolaulimalide, new paclitaxel-like microtubule-s tabilizing agents, Cancer Res., 59, 653

Hood, 2001, The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C, Anticancer Drug Des., 16, 155

Gamble, 1999, Cytotoxic and tubulin-interactive hemiasterlins from #Auletta# and Siphonochalina spp. sponges, Bioorg. Med. Chem., 7, 1611, 10.1016/S0968-0896(99)00089-9

Edler, 2002, Inhibition of tubulin polymerisation by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin-10, Biochem. Pharmacol., 63, 707, 10.1016/S0006-2952(01)00898-X

Kowalski, 1997, The microtubule-stabilzing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits growth of paclitaxel-resitant cell lines, Mol. Pharmacol., 52, 613, 10.1124/mol.52.4.613

Anthoney, 2001, DNA: still a target worth aiming at? A Review of new DNA-interactive agents, Am. J. Pharmacogenomics, 1, 67, 10.2165/00129785-200101010-00008

Rinehart, 2000, Antitumor compounds from tunicates, Med. Res. Rev., 20, 1, 10.1002/(SICI)1098-1128(200001)20:1<1::AID-MED1>3.0.CO;2-A

Burres, 1989, Antitumor activity and nucleic acid binding properties of dercitin, a new acridine alkaloid isolated from marine Dercitus species sponge, Cancer Res., 49, 5267

Burres, 1991, Antitumor activity and biochemical effects of topsentin, Biochem. Pharmacol., 42, 745, 10.1016/0006-2952(91)90031-Y

Corey, 1996, Enantioselective total synthesis of ecteinascidin 743, J. Am. Chem. Soc., 118, 9202, 10.1021/ja962480t

Cuevas, 2000, Synthesis of ecteinascidin ET-743 and phthalascidin PT-650 from cyanosafracin B, Org. Lett., 2, 2545, 10.1021/ol0062502

Martinez, 2001, Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650, Chem. Biol., 8, 1151, 10.1016/S1074-5521(01)00082-5

Aune, 2002, Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action, Anticancer Drugs, 13, 545, 10.1097/00001813-200207000-00001

Minuzzo, 2000, Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743, Proc. Natl. Acad. Sci. U. S. A., 97, 6780, 10.1073/pnas.97.12.6780

Friedman, 2002, Ecteinascidin-743 inhibits activated but not constitutive transcription, Cancer Res., 15, 3377

Kanzaki, 2002, Overcoming multidrug resistance P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743, Mol. Cancer Ther., 1, 1327

Li, 2001, Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent, Clin. Cancer Res., 7, 2908

Takebayashi, 2001, Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide excision repair, Nat. Med., 7, 961, 10.1038/91008

Damia, 2001, Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA repair pathways, Int. J. Cancer, 92, 583, 10.1002/ijc.1221

Takahashi, 2001, Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells, Clin. Cancer Res., 7, 3251

Verschraegen, 2001, ET-743 (PharmaMar/NCI/Ortho Biotech), Curr. Opin. Investig. Drugs, 2, 1631

Garcia-Fernandez, 2002, Aplidin™ induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase Cδ, Oncogene, 21, 7533, 10.1038/sj.onc.1205972

Cuadrado, 2003, Aplidin™ induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK, J. Biol. Chem., 278, 241, 10.1074/jbc.M201010200

Hamann, 1996, Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp, J. Org. Chem., 61, 6594, 10.1021/jo960877+

Kobayashi, 1995, KRN7000, a novel immunomodulator, and its antitumor activities, Oncol. Res., 7, 529

Chen, 1999, The angiostatic sterol squalamine is a calmodulin chaperone, Clin. Cancer Res., 5, 3768S

Burgoyne, 1992, Contignasterol, a highly oxygenated steroid with the unnatural 14.beta. configuration from the marine sponge Petrosia contignata Thiele, 1899, J. Org. Chem., 57, 525, 10.1021/jo00028a024

Rudi, 1994, Amino acid derivatives from the marine sponge Jaspis digonoxea, J. Nat. Prod., 57, 829, 10.1021/np50108a023

Tulp, 2002, Functional versus chemical diversity: is biodiversity important for drug discovery?, Trends Pharmacol. Sci., 23, 225, 10.1016/S0165-6147(02)02007-2

Cragg, 2002, Chemical diversity: a function of biodiversity, Trends Pharmacol. Sci., 23, 404, 10.1016/S0165-6147(02)02099-0

Tulp, 2002, Chemical diversity: independent of functional diversity, Trends Pharmacol. Sci., 23, 405, 10.1016/S0165-6147(02)02100-4

Reynolds, 1999, A natural edge: nature still offers the greatest drug diversity, J. Natl. Cancer Inst., 91, 1608, 10.1093/jnci/91.19.1608

Rayl, 1999, Oceans: medicine chests of the future?, The Scientist, 13, 1